FDA Oks Pfizer Rare Blood Cancer Drug

Aug 21, 2017

Motley Fool

The U.S. FDA has green lighted Pfizer's rare blood cancer drug, Besponsa, with a boxed warning.

After failing in a clinical trial evaluating its effectiveness in a subset of non-Hodgkin lymphoma patients, Besponsa was found to be effective in treating cancer in patients diagnosed with relapsing or refractory B-cell precursor acute lymphoblastic leukemia.

The boxed warning cautions that patients treated with Besponsa are at a risk of severe liver damage, as well as an increased risk of death for those who take the drug after receiving a specific type of stem cell transplant.

The approval is a win for Pfizer as it looks to establish itself as a leading cancer giant. Besponsa will join the ranks of Pfizer's fast-growing breast cancer drug Ibrance, kidney cancer drug Sutent, and the lung cancer drug Xalkori.

Read the Motley Fool coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments